MR Antagonist and LSD1
Launched by BRIGHAM AND WOMEN'S HOSPITAL · Apr 7, 2021
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new way to treat high blood pressure (hypertension) in Black individuals who have a specific genetic marker known as the LSD1 risk allele. The researchers want to see if a special type of treatment directed by this genetic information can better control blood pressure and prevent kidney damage compared to standard treatments. This could help about 30% of people with essential hypertension who are Black and carry this genetic risk.
To participate in the trial, individuals need to be over 17 years old, identify as Black, and either currently have high blood pressure or have been treated for it. They should also be carrying the rs587168 allele and not be on more than two other blood pressure medications. Participants can expect to undergo various health tests to ensure they are suitable for the study and will receive close monitoring throughout the trial. This research could lead to more personalized and effective treatment options for those with this specific genetic makeup.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • untreated as well as currently treated hypertensives
- • rs587168 allele carriers
- • not on more than two anti-hypertensives
- • normal renal, metabolic, electrolyte, and CBC laboratory tests
- • self-identified Black race
- • age \>17 yrs.
- Exclusion Criteria:
- • known cardiac disease other than HTN
- • renal, circulatory or neurologic diseases
- • diabetes
- • smoking
- • secondary HTN as indicated by history, physical examination or screening blood and urine tests
- • smoking
- • any drug therapy, except for anti-hypertensives and stable thyroid medication replacement
About Brigham And Women's Hospital
Brigham and Women's Hospital (BWH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As an integral part of the Partners HealthCare system, BWH combines cutting-edge medical education with a focus on patient-centered care, fostering an environment that promotes groundbreaking clinical trials across various specialties. The hospital is dedicated to translating scientific discoveries into effective treatments, making significant contributions to the fields of cardiovascular medicine, oncology, and women's health, among others. With a robust infrastructure for research and a collaborative approach, BWH aims to improve patient outcomes and enhance the overall quality of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Andrea Haas, MD
Principal Investigator
Brigham and Women's
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials